Drug Pricing Transparency: How And Where You’ll Be Impacted
On the tailwind of several high-profile drug pricing increases, and resulting media firestorms, we’re seeing intense focus on pharmaceutical pricing practices.
States and the federal government are both reacting strongly — 2016 saw a record number of policy initiatives aimed at curbing price increases and demanding financial explanations from manufacturers, health plans, and pharmacy benefit managers (PBMs), often under the guise of transparency. Each of these three policy areas carried its own distinct features, commonly replicated across state lines where bills were introduced.
Knowing the overall shape these public policy efforts took in 2016 will be crucial for anticipating and understanding what the landscape will look like when lawmakers convene in 2017.
The 21 page comprehensive report is now available for purchase, Click here for more information and a link to the AMCP store.
“Trends in Pharmaceutical Drug Pricing Transparency” to discover
how and where these new policies may affect your business.
This report is available to all SAFPhIR subscribers as part of their annual subscription. We are making this timely and important report available for purchase to non-subscribers. Non-subscribing AMCP members get a discount.
SAFPhIR is the one depository where your managed care and pharmaceutical leaders can research and track all the regulatory and legislative requirements that impact your business. We help executive leadership make well-informed business and operational decisions with confidence that they’ve considered the various requirements. Review executive trend and analysis pieces, dig into the granular data points at the Board of Pharmacy level, or request custom research.